Skip to main content
. 2022 Sep 6;13:963638. doi: 10.3389/fphar.2022.963638

FIGURE 1.

FIGURE 1

CHMACS inhibits the activity of CC cells in vivo (A) Composition of CHMACS. (B) Tumor morphology. (C) Hematoxylineosin staining of tumor tissues; **p < 0.01 vs. control; n = 6; t-test. (D) Tumor weight and (E) volume; **p < 0.01 vs. control; n = 6; t-test. (F) Immunohistochemical staining to assess proportion of cells that were positive for Ki67; *p < 0.05 vs. control; n = 6; t-test. (G) Western blotting data.